CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.01M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.01M.
Overvalued
The company’s latest PE is -0.79, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.35M shares, decreasing 68.39% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 202.18 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.66.